Spyre Therapeutics, Inc. — Director's Dealing 2017

Aug 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-08-22

Reporting Person: Wooldridge James (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-22	Employee Stock Option (right to buy)	$3.1	A	165000	Acquired	2027-08-21	Common Stock (165000)	Direct
2017-08-22	Employee Stock Option (right to buy)	$3.1	A	10000	Acquired	2027-08-21	Common Stock (10000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on July 10, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F2: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.